Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
1.25B | 682.16M | 556.38M | 1.60B | 1.15B | 475.60M | Gross Profit |
1.11B | 479.42M | 212.61M | 696.31M | 1.13B | -271.43M | EBIT |
411.41M | -248.93M | -566.51M | -644.74M | -1.69B | -416.72M | EBITDA |
536.50M | -108.04M | -487.39M | -604.71M | -1.68B | -398.23M | Net Income Common Stockholders |
478.70M | -187.50M | -545.06M | -657.94M | -1.74B | -427.50M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
731.48M | 923.12M | 568.50M | 1.34B | 1.52B | 711.05M | Total Assets |
1.29B | 1.56B | 1.80B | 2.26B | 2.58B | 1.58B | Total Debt |
228.66M | 230.42M | 229.08M | 549.78M | 453.99M | 322.04M | Net Debt |
-34.68M | -299.81M | -339.42M | -787.10M | -1.06B | -231.36M | Total Liabilities |
1.37B | 2.18B | 2.51B | 2.89B | 2.93B | 955.27M | Stockholders Equity |
-75.64M | -623.84M | -716.93M | -634.08M | -351.67M | 627.21M |
Cash Flow | Free Cash Flow | ||||
-196.56M | -100.32M | -772.77M | -508.92M | 265.46M | -97.16M | Operating Cash Flow |
-189.21M | -87.26M | -713.97M | -415.94M | 322.95M | -42.54M | Investing Cash Flow |
-270.11M | -204.04M | -58.81M | -92.98M | 100.15M | -377.78M | Financing Cash Flow |
247.64M | 260.58M | 4.47M | 324.99M | 461.71M | 984.76M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | $961.42M | 4.48 | 34.46% | ― | 799.36% | ― | |
67 Neutral | $1.17B | 2.67 | 30.06% | ― | 25.92% | ― | |
62 Neutral | $693.22M | ― | -40.13% | ― | ― | -3.08% | |
62 Neutral | $1.80B | ― | -5.78% | ― | 25.50% | 64.63% | |
56 Neutral | $901.42M | ― | -15.59% | ― | -35.41% | -12.26% | |
54 Neutral | $5.38B | 3.40 | -45.06% | 3.28% | 16.75% | -0.02% | |
42 Neutral | $987.42M | ― | -51.85% | ― | ― | 0.71% |
On June 11, 2025, Novavax announced promising results from the initial cohort of its Phase 3 trial for the COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. Both vaccines demonstrated robust immune responses and were well tolerated, showing potential for further development and partnerships. The trial, involving approximately 2,000 adults aged 65 and older, compared these candidates to licensed vaccines Nuvaxovid and Fluzone HD, with results indicating similar immunogenicity and safety profiles. These findings support Novavax’s strategy to pursue partnering opportunities and advance its vaccine programs.
The most recent analyst rating on (NVAX) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Novavax stock, see the NVAX Stock Forecast page.
On May 27, 2025, Novavax, Inc. announced the elimination of the Chief Operating Officer position, resulting in the termination of John Trizzino’s employment effective June 20, 2025. Following his departure, Mr. Trizzino will continue to provide consulting services to the company until December 31, 2025, under a new consulting agreement. The separation agreement includes a lump sum payment and COBRA premium coverage for Mr. Trizzino, while the consulting agreement ensures a monthly fee and continued vesting of his equity awards.
The most recent analyst rating on (NVAX) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Novavax stock, see the NVAX Stock Forecast page.
On May 16, 2025, Novavax announced that the FDA approved its Biologics License Application for Nuvaxovid™, a COVID-19 vaccine for adults 65 and older and individuals 12-64 with high-risk conditions. This approval triggered a $175 million milestone payment from Sanofi Pasteur Inc. and requires a new Phase 4 trial for individuals aged 50-64 without high-risk conditions. Novavax plans to deliver the 2025-2026 vaccine formula in the U.S. this fall, pending FDA strain recommendations.
The most recent analyst rating on (NVAX) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Novavax stock, see the NVAX Stock Forecast page.
On April 25, 2025, Novavax, Inc. expanded its Board of Directors from eight to nine members by appointing Charles W. Newton as a Class III director. Mr. Newton will serve until the company’s 2025 annual stockholders meeting and is eligible for compensation under the company’s Non-Employee Director Compensation Policy, which includes cash and equity grants. The Board determined Mr. Newton is independent under Nasdaq listing standards, and he will enter into the company’s standard indemnification agreement.
On April 23, 2025, Novavax announced that their Biologics License Application is considered approvable by the FDA, following discussions up to April 1. The FDA has requested additional clinical data as a post-marketing commitment, and Novavax plans to address this request promptly to secure approval.